QPPV.COM

Drug-Induced QT Prolongation: Cardiac Safety Assessment in Clinical Development and Pharmacovigilance

Understand how drug-induced QT prolongation is identified and evaluated, why QTc prolongation is an imperfect marker of proarrhythmic risk, how E14 and S7B integrate clinical and nonclinical evidence, and how safety physicians assess cardiac safety during development and after approval.

Audio Lesson 10 min
Knowledge Assessment Test your understanding of this article. Take the assessment →

Drug-Induced QT Prolongation: Cardiac Safety Assessment in Clinical Development and Pharmacovigilance

Introduction

Cardiac safety is a central component of medicinal-product development because cardiovascular adverse effects can occur through several mechanisms, including effects on cardiac electrophysiology, myocardial function, vascular tone and cardiac conduction.

Among these concerns, drug-induced prolongation of the QT interval has received particular regulatory attention.

The QT interval represents the duration from ventricular depolarisation to the completion of ventricular repolarisation on the electrocardiogram (ECG). Drugs that delay ventricular repolarisation can prolong the QT interval and, in susceptible circumstances, increase the risk of ventricular tachyarrhythmias including torsade de pointes.

The important distinction is that QT or QTc prolongation is not synonymous with torsade de pointes.

QTc is a biomarker of altered ventricular repolarisation. It is useful because excessive QT prolongation can indicate a potential proarrhythmic liability, but QTc alone does not directly measure an individual's probability of developing torsade de pointes.

This distinction is fundamental to modern cardiac-safety assessment.

The regulatory framework therefore does not rely exclusively on whether a drug prolongs QTc. Clinical ECG findings, drug exposure, pharmacology, nonclinical electrophysiology, adverse events, patient risk factors and the totality of evidence are considered together.

The ICH E14 guideline addresses clinical evaluation of QT/QTc prolongation and proarrhythmic potential for non-antiarrhythmic drugs, while ICH S7B addresses nonclinical evaluation of delayed ventricular repolarisation. The 2022 E14/S7B Questions and Answers further developed an integrated approach to these assessments. [1][2][3]

For pharmacovigilance professionals, the practical question is therefore not simply:

"Does the drug prolong QTc?"

The more useful question is:

"What does the totality of clinical, pharmacological, nonclinical and exposure-related evidence indicate about the drug's proarrhythmic risk?"

Learning Objectives

After reading this article, the reader should be able to:

Understanding QT and QTc

What Is the QT Interval?

The QT interval is measured on the surface ECG from the beginning of the QRS complex to the end of the T wave.

It represents the combined duration of ventricular depolarisation and repolarisation.

Because ventricular repolarisation is influenced strongly by heart rate, the raw QT interval cannot be interpreted consistently across different heart rates.

A faster heart rate generally produces a shorter QT interval.

A slower heart rate generally produces a longer QT interval.

Consequently, cardiac-safety assessment commonly uses a heart-rate-corrected QT interval, referred to as QTc.

Why QTc Is Used

QTc attempts to account mathematically for the effect of heart rate on the measured QT interval.

Several correction methods exist.

The most familiar include:

Different correction methods behave differently at extremes of heart rate.

For this reason, the choice of correction method should be predefined and scientifically justified rather than selected after reviewing the results.

Fridericia correction is frequently used in clinical development because it can perform better than Bazett correction across relevant heart-rate ranges, although the appropriate method depends on the study and dataset.

QTc Is an Estimate, Not a Direct Measurement of Risk

A corrected QT value should not be interpreted as a direct measurement of proarrhythmic risk.

The relationship between QT prolongation and torsade de pointes is influenced by:

The ICH S7B framework recognises that ventricular repolarisation is a complex physiological process involving multiple ion channels and other determinants. [2]

Why Drug-Induced QT Prolongation Matters

Ventricular Repolarisation

Ventricular repolarisation depends on coordinated movement of ions across cardiac-cell membranes.

Potassium currents are particularly important during the repolarisation phase.

Inhibition of the rapid delayed rectifier potassium current, commonly referred to as IKr, can delay repolarisation and increase QT duration.

The human ether-à-go-go-related gene (hERG) potassium channel is an important molecular component associated with this current.

However, cardiac electrophysiology is more complex than a single-channel model.

A drug may affect multiple ion channels simultaneously, and the net electrophysiological effect can depend on the balance between these actions.

From QT Prolongation to Torsade de Pointes

Torsade de pointes is a distinctive form of polymorphic ventricular tachycardia that can occur in the setting of prolonged ventricular repolarisation.

It can terminate spontaneously, but it can also deteriorate into ventricular fibrillation and sudden cardiac death.

The risk is therefore clinically important.

However, not every drug that prolongs QTc produces torsade de pointes.

This is one reason that modern regulatory evaluation considers more than QTc magnitude alone.

A drug may produce measurable QTc prolongation without producing a clinically important proarrhythmic signal, particularly when the effect is modest and other evidence indicates low risk.

Conversely, a serious arrhythmic risk may not always be adequately represented by a single QTc measurement.

Risk Factors for Torsade de Pointes

Factors that can increase susceptibility include:

The presence of several risk factors may substantially alter the interpretation of an otherwise modest QTc change.

A safety physician should therefore evaluate the patient rather than treating QTc as an isolated numerical variable.

Individual-Subject QTc Assessment

Confirm the ECG Data

The first step in evaluating a potentially important QT finding is to confirm the underlying ECG data.

The reviewer should establish:

A single questionable ECG should not automatically be interpreted as evidence of a drug-related cardiac effect.

Baseline QTc

Baseline QTc provides the reference against which treatment-emergent changes are evaluated.

Important questions include:

A subject with a high baseline QTc may have a different risk profile from a subject with a low baseline QTc even if both experience the same treatment-emergent increase.

Change From Baseline

Clinical trials commonly evaluate the change in QTc from baseline.

A treatment-emergent change may be expressed as:

ΔQTc = QTc after treatment − QTc at baseline

The change can then be evaluated at different time points and concentrations.

The maximum observed change is useful, but it should not automatically be treated as the most clinically meaningful observation.

The timing of the ECG relative to drug exposure is important.

QTc Outliers

Clinical-development programmes may use predefined QTc thresholds and changes from baseline to identify subjects requiring review.

Potentially important findings can include:

The precise criteria should be defined prospectively according to the development programme and applicable regulatory framework.

Outlier analysis is a screening mechanism.

It does not by itself establish causality.

Population-Level QT Assessment

Why Individual Cases Are Not Enough

A drug's QT effect is fundamentally a population-level development question as well as an individual-subject question.

A clinical trial may contain hundreds or thousands of ECG measurements.

The analysis therefore considers:

The objective is to estimate the drug-related change in QTc and understand its relationship with exposure.

Treatment Versus Control

A change in QTc observed during treatment must be interpreted against an appropriate control.

This is important because QTc naturally varies over time.

Placebo-adjusted analyses can help distinguish drug-related changes from:

The comparison with control therefore provides important context for interpretation.

Time-Matched Analysis

QTc effects may vary over the dosing interval.

ECGs should therefore be considered in relation to pharmacokinetic exposure and the expected time of maximum effect.

A drug may produce a measurable effect at one time point but not another.

Repeated ECG measurements can therefore provide a more informative picture than a single post-dose measurement.

Concentration-QTc Analysis

The Exposure-Response Relationship

One of the most important developments in modern QT assessment is concentration-QTc analysis.

Instead of asking only whether QTc changed after dosing, investigators can evaluate whether QTc changes increase with drug concentration.

A typical model considers:

QTc change = intercept + slope × drug concentration

The exact statistical model depends on the study design and data.

The objective is to estimate the relationship between exposure and QTc while accounting for relevant sources of variability.

Why Concentration-QTc Analysis Is Valuable

Concentration-QTc analysis can be particularly useful when:

The analysis can help determine whether clinically relevant QT effects occur at therapeutic and supratherapeutic exposures.

It can also support interpretation of QT effects in patient populations.

Exposure Is More Informative Than Dose Alone

Dose does not always correspond directly to systemic exposure.

Exposure can vary because of:

Consequently, exposure-response analysis can provide a more mechanistic understanding of QT effects than dose-response analysis alone.

Thorough QT/QTc Studies

Purpose of a Thorough QT Study

The traditional thorough QT/QTc study is designed to determine whether a drug has a threshold pharmacological effect on cardiac repolarisation.

It generally compares the investigational drug with placebo and includes a positive control capable of demonstrating assay sensitivity.

The traditional regulatory framework focuses on the upper confidence bound around the estimated mean QTc effect.

The ICH E14 guideline describes a threshold of regulatory concern around 5 milliseconds, with an upper bound of the two-sided 90% confidence interval around the mean effect of 10 milliseconds. [1]

The purpose is to detect a drug effect on QT/QTc.

It is not a direct test of whether a drug causes torsade de pointes.

Positive Control

A positive control demonstrates that the study can detect a small QTc effect.

This is important because a negative study is only informative if the study had sufficient assay sensitivity and appropriate design.

Failure to observe QTc prolongation is therefore interpreted in the context of:

When a Traditional Thorough QT Study May Not Be Appropriate

Drug development has evolved beyond a single standardised study design.

The E14/S7B framework permits integrated approaches using clinical and nonclinical evidence.

Depending on the product and development programme, concentration-QTc analysis and other evidence may provide an appropriate assessment.

The decision should be scientifically justified and aligned with the applicable regulatory framework.

ICH E14: Clinical QT Assessment

Purpose of E14

ICH E14 provides the clinical framework for evaluating QT/QTc prolongation and proarrhythmic potential for non-antiarrhythmic drugs.

It addresses:

The guideline was originally established to standardise evaluation of potential drug-related QT prolongation.

Subsequent questions and answers have refined its application.

The 2022 E14/S7B Questions and Answers

The 2022 ICH E14/S7B Questions and Answers are particularly important because they clarify how clinical and nonclinical evidence can be integrated.

The document addresses the implementation of E14 and S7B and adds questions concerning nonclinical testing and integrated assessment. [3]

The resulting approach is less dependent on a single study and more focused on the totality of evidence.

ICH S7B: Nonclinical Assessment

Purpose of S7B

ICH S7B addresses nonclinical evaluation of the potential for delayed ventricular repolarisation.

It includes:

The objective is to identify potential proarrhythmic liability before and alongside clinical development.

hERG and Beyond

The hERG channel is an important component of the IKr current and has historically been central to nonclinical QT assessment.

However, hERG inhibition alone does not completely describe clinical proarrhythmic risk.

A drug may affect multiple ion channels.

Some drugs can therefore produce a net electrophysiological effect that differs from what would be predicted from hERG inhibition alone.

The modern framework consequently considers integrated electrophysiological evidence rather than treating one assay as a complete surrogate for clinical risk.

In Vivo Repolarisation Assessment

In vivo studies can provide information about:

These data can complement in vitro findings.

The interpretation should consider whether observed effects occur at clinically relevant exposures.

The Integrated E14/S7B Framework

From Separate Tests to Totality of Evidence

The most important conceptual development is the integration of clinical and nonclinical information.

Relevant evidence can include:

The objective is to understand the probability and circumstances of clinically meaningful proarrhythmic risk.

Low Proarrhythmic Risk

A conclusion of low proarrhythmic risk should not be based on one negative test.

It should be supported by a coherent totality of evidence.

For example:

The precise regulatory conclusion depends on the product and evidence available.

Positive Findings Require Context

A QTc signal should trigger further assessment rather than automatic conclusions.

The reviewer should ask:

This approach prevents numerical QTc thresholds from replacing clinical reasoning.

Factors That Modify QT Risk

Electrolytes

Electrolyte abnormalities can increase susceptibility to ventricular arrhythmia.

Important abnormalities include:

A QTc measurement obtained during significant electrolyte disturbance may therefore have a different clinical meaning from the same measurement obtained under stable physiological conditions.

Bradycardia

Bradycardia can increase susceptibility to torsade de pointes in the presence of delayed repolarisation.

The heart rate should therefore always be considered when reviewing a QT-related event.

Structural Heart Disease

Structural cardiac disease can increase arrhythmic vulnerability.

Relevant conditions may include:

The complete cardiovascular history is therefore relevant to case assessment.

Concomitant QT-Prolonging Medicines

Concomitant medicines may increase risk through:

The medication history should therefore include prescription medicines, non-prescription medicines and other relevant substances.

ECG Measurement and Data Quality

Manual Versus Automated Measurement

Automated ECG systems can improve consistency and efficiency, but QT measurement can be challenging.

The end of the T wave may be difficult to define when:

Important ECG findings should therefore be reviewed according to the study's predefined methodology.

Lead Selection

QT measurement can vary between ECG leads.

A consistent methodology is important for longitudinal clinical-trial assessment.

The study should define:

Replicate ECGs

Replicate ECG measurements can reduce random measurement variability.

They may be particularly useful when small changes are being evaluated.

This is important because regulatory QT assessment may depend on detecting relatively small treatment effects.

Cardiac Safety in Clinical Development

Individual-Subject Review

Individual review may be appropriate for subjects with:

The reviewer should integrate:

Population-Level Review

At the population level, the safety team may examine:

The purpose is to determine whether a coherent treatment-related cardiac signal exists.

Treatment Discontinuation and Clinical Actions

A QT-related finding may lead to:

The appropriate action depends on the clinical circumstances and protocol.

QTc prolongation should not be treated as a universal automatic stopping rule.

Post-Marketing Pharmacovigilance

Sources of Cardiac Safety Information

After approval, QT-related information can arise from:

Post-marketing reports are often less complete than clinical-trial ECG datasets.

A spontaneous report may describe:

without containing a QTc measurement.

Such cases should not automatically be excluded from cardiac-safety evaluation simply because a QTc value is unavailable.

Case-Level Medical Review

The reviewer should establish:

The purpose is to determine whether the event is medically compatible with a drug-related proarrhythmic effect.

Aggregate Safety Assessment

At the aggregate level, the safety team should consider whether multiple reports demonstrate:

A cluster of serious ventricular arrhythmias may be clinically important even when individual reports are incomplete.

Worked Examples

Example 1: QTc Increase Without Arrhythmia

A subject has:

Baseline QTc = 420 ms

Post-treatment QTc = 455 ms

The change is:

ΔQTc = +35 ms

The finding warrants review, but the number alone does not establish clinically important proarrhythmic risk.

The reviewer should assess:

Example 2: Marked QTc With Hypokalaemia

A subject develops:

QTc = 510 ms

At the same time:

This is a high-priority medical review.

The QTc value is important, but the clinical interpretation requires consideration of multiple interacting risk factors.

Correction of the electrolyte abnormality, review of concomitant medicines and repeat ECG assessment may be appropriate according to the clinical situation.

Example 3: Concentration-Dependent QTc Effect

A clinical trial demonstrates increasing QTc changes with increasing plasma concentrations.

The effect is:

This pattern supports a pharmacological exposure-response relationship.

The development team should then determine whether the observed exposure range is clinically relevant and integrate the findings with nonclinical and clinical safety evidence.

Example 4: Torsade de Pointes With Incomplete ECG Data

A post-marketing report describes syncope followed by documented torsade de pointes.

The report lacks a pre-event QTc measurement.

The absence of a QTc value does not eliminate the case from cardiac-safety evaluation.

The reviewer should examine:

A clinically important arrhythmic event can therefore remain highly relevant even when the classical QT measurement is unavailable.

Limitations of QTc Assessment

QTc Is Not Torsade de Pointes

The most important limitation is conceptual.

QTc prolongation is an electrophysiological biomarker.

Torsade de pointes is a clinical arrhythmia.

The two are related but not interchangeable.

QT Correction Is Imperfect

Every correction formula has limitations.

Heart-rate correction can be imperfect, particularly at extreme heart rates.

The choice of formula can therefore influence the apparent magnitude of a treatment effect.

Consistency and prespecification are essential.

Measurement Variability

QT measurement itself introduces variability.

Small changes may therefore be difficult to distinguish from measurement noise unless ECG collection and analysis are carefully controlled.

QTc Does Not Capture All Proarrhythmic Mechanisms

Some arrhythmic mechanisms may not be adequately predicted by QTc prolongation.

This reinforces the importance of considering:

QTc and Proarrhythmic Risk Are Not Linear

The relationship between QTc prolongation and arrhythmic risk is not a simple one-to-one relationship.

Risk depends on the drug, patient, exposure and physiological environment.

This is why a single universal QTc threshold cannot substitute for clinical assessment.

Practical Medical Review Framework

Step-by-Step QT Safety Review

A structured review may proceed through the following sequence:

  1. Confirm the ECG measurement.
  2. Confirm the QT correction method.
  3. Confirm the baseline QTc.
  4. Determine the change from baseline.
  5. Review heart rate.
  6. Review ECG timing relative to dosing.
  7. Review drug concentration where available.
  8. Review electrolytes.
  9. Review concomitant medicines.
  10. Review relevant cardiac history.
  11. Assess symptoms and clinical events.
  12. Review repeat ECGs.
  13. Assess dechallenge where relevant.
  14. Evaluate exposure-response relationships.
  15. Consider nonclinical evidence.
  16. Determine whether the overall evidence supports a drug-related effect.
  17. Document the medical rationale.

Medical Documentation

An important QT-related assessment should document, as appropriate:

The documentation should allow another medically qualified reviewer to reconstruct the reasoning.

Pharmacovigilance and Inspection Considerations

Inspection Perspective

An organisation should be able to demonstrate that potential cardiac-safety signals were systematically identified, reviewed and escalated.

Relevant evidence may include:

The existence of a QT analysis alone is not sufficient.

The organisation should be able to demonstrate how findings were interpreted and what decisions resulted.

Common Documentation Weaknesses

Potential weaknesses include:

Good documentation should allow an independent reviewer to understand both the data and the medical reasoning.

Common Mistakes in QT Safety Assessment

Common errors include:

What an Experienced Safety Physician Looks For

An experienced safety physician does not begin with:

"Is the QTc above the threshold?"

The first questions are:

"Is the ECG reliable, and what is the clinical context?"

The reviewer then considers:

Only after these questions have been considered should the reviewer decide whether the findings represent a meaningful drug-related cardiac-safety signal.

This approach prevents a numerical ECG threshold from replacing clinical judgement.

QT Safety Compared With Liver and Kidney Safety

The three organ-safety frameworks illustrate an important principle.

For liver safety, Hy's Law and eDISH provide structured approaches to identifying concerning hepatocellular injury patterns.

For kidney safety, there is no single equivalent rule. Assessment integrates kidney function, injury, phenotype, biomarkers and clinical context.

For cardiac safety, QT/QTc assessment and the E14/S7B framework provide a structured approach to evaluating ventricular repolarisation and proarrhythmic potential.

These frameworks are therefore not interchangeable.

Each reflects the biology of the organ system and the way serious toxicity becomes detectable.

The common pharmacovigilance principle is:

identify the relevant phenotype, establish the biological context, compare exposure and control, evaluate competing explanations, and integrate the totality of evidence.

Key Takeaways

Drug-induced QT prolongation is an important cardiac-safety consideration during clinical development and pharmacovigilance.

The QT interval reflects ventricular depolarisation and repolarisation, while QTc attempts to account for heart-rate effects.

QTc prolongation is an important biomarker but is not equivalent to torsade de pointes and is not a direct individual-patient measure of proarrhythmic risk.

A robust assessment considers:

ICH E14 provides the clinical framework for QT/QTc assessment, while ICH S7B provides the nonclinical framework for delayed ventricular repolarisation.

The 2022 E14/S7B Questions and Answers emphasise integration of clinical and nonclinical evidence rather than reliance on a single test.

The most important principle is:

QTc prolongation is a safety signal that requires interpretation; it is not an automatic diagnosis of proarrhythmia.

References

  1. International Council for Harmonisation. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs.

  2. International Council for Harmonisation. S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals.

  3. U.S. Food and Drug Administration. E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential—Questions and Answers. Guidance for Industry. August 2022.

  4. U.S. Food and Drug Administration. QTc Information in Human Prescription Drug and Biological Product Labeling. Guidance for Industry. December 2025.

Revision History

Related Articles

Drug-Induced Cardiac Toxicity: Cardiovascular Safety Assessment in Clinical Development and Pharmacovigilance

Understand how potential drug-induced cardiac toxicity is identified and medically evaluated, how ICH E14 and S7B support assessment of QT/QTc and proarrhythmic risk, and how cardiovascular safety signals are assessed across clinical development and pharmacovigilance.

Drug-Induced Hematologic Toxicity: Hematologic Safety Assessment in Clinical Development and Pharmacovigilance

Understand how drug-induced hematologic toxicity is recognised and medically evaluated, how cytopenias are characterised by lineage, severity and mechanism, and how hematologic safety signals are assessed across clinical development and pharmacovigilance.

Drug-Induced Kidney Injury: Renal Safety Assessment in Clinical Development and Pharmacovigilance

Understand how drug-induced kidney injury is identified and medically evaluated, why kidney function and kidney injury are not the same, how renal biomarkers support clinical-trial safety assessment, and how pharmacovigilance teams evaluate potential nephrotoxicity.